San Antonio Breast Cancer Symposium (SABCS)

The addition of palbociclib to letrozole did not show clinical benefit as a neoadjuvant therapy, but did enhance the suppression of malignant cell proliferation.

The results of the TAM-01 phase III trial suggest that the dose of tamoxifen can be lowered to achieve better safety without compromising efficacy.

Adjuvant chemotherapy was linked to improved overall survival in older adults with breast cancer.

Adjuvant trastuzumab emtansine showed improved invasive disease-free survival compared with trastuzumab in HER2-positive early breast cancer.

New research may help identify new candidate targets and stratify patients eligible for innovative therapies.

Adjuvant capecitabine provided no survival benefit for patients with early triple-negative breast cancer, except for those with nonbasal-like disease.

Results from the largest metastatic ILC series in which matched primary tumor and metastases samples were interrogated.

PD-L1 expression by tumor-infiltrating immune cells was found to be the most predictive biomarker for survival outcomes for patients with advanced TNBC in the IMpassion130 trial.

Valuable insights revealed from the characterization of the tumor microenvironment of thousands of early and metastatic breast cancer cells.